Regenxbio Inc (RGNX.O) said Wednesday its experimental gene therapy for Duchenne muscular dystrophy showed continued muscle function improvements in early-stage trial data. The results support the company’s plan to file for accelerated FDA approval by mid-2026, potentially offering new hope for...